Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. - Wikidata - awgldk - TriplyDB

Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.

Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.

http://www.wikidata.org/entity/Q37809940

about

Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma Progress in systemic therapy of advanced hepatocellular carcinoma Optimal combination of antiangiogenic therapy for hepatocellular carcinoma Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics Recent advances in multidisciplinary management of hepatocellular carcinoma Systemic therapy of hepatocellular carcinoma: current status and future perspectives Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience.Hepatocellular Cancer: New Kids on the Block Current systemic treatment of hepatocellular carcinoma: A review of the literature Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis?Challenges of advanced hepatocellular carcinoma Combination treatment including targeted therapy for advanced hepatocellular carcinoma Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients Comparison of hepatocellular carcinoma in Eastern versus Western populations.Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents.Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: a multicenter, open-label, single-arm phase II study.First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study.A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma.Systemic therapy for advanced hepatocellular carcinoma: an update.Cirrhosis and its complications: evidence based treatment.New knowledge of the mechanisms of sorafenib resistance in liver cancer Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models Dehydroepiandrosterone-induces miR-21 transcription in HepG2 cells through estrogen receptor β and androgen receptor Systemic treatment of hepatocellular carcinoma: Past, present and future Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply.Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma.Rapamycin enhances cetuximab cytotoxicity by inhibiting mTOR-mediated drug resistance in mesenchymal hepatoma cells.Laser ablation for small hepatocellular carcinoma.Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.Oncolytic immunotherapy using recombinant vaccinia virus GLV-1h68 kills sorafenib-resistant hepatocellular carcinoma efficiently.Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study Drug development for hepatocellular carcinoma: knowing the past helps to understand the future Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials.An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma.Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma.Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts.

P2860

Q24635267-F408C2D6-EC55-45ED-AF1F-440D199AAB60 Q26740217-CE877929-B003-4053-B216-11F0AAAC0DD9 Q26799458-4270CF46-62F3-4590-812F-5A2833AD85C2 Q26851272-743FB927-8B8C-4FC0-91AE-ACC008BCE01D Q26863748-981D4F3D-EE5E-4A6C-A10F-30055F2DFE4E Q26865844-0F10BD79-2913-4477-A189-374E762200D0 Q26998606-7723714C-F11A-4AF2-BCD0-A78ED7D8345C Q27022642-ECC1361F-758E-42FE-8BC6-1FECF9B383B9 Q27026036-6256CA77-B38D-4049-9DF3-5531032A1EDA Q27026453-02A9A4BC-FB5C-4823-B671-5E1EA992B84A Q28068710-F79B4D66-9733-4467-A8CE-4A2F22F30F9E Q28076867-36893916-856D-4D7B-A511-C4638BC5C641 Q28077738-17A1A1B6-190F-46BD-B074-73ABD901A0C3 Q28079328-DD215F3B-4F09-47C7-8694-528B1A227742 Q30245396-CE4BC712-9236-4468-8249-275C223E5AED Q30249335-1B59EE91-5A9B-470B-8D52-0E781D254BD2 Q33415172-C53103B3-7CB3-4D3E-A20E-8F7BD8B41E1B Q33420684-D5D99C2D-4178-4F98-87BA-59D6A2AAEE65 Q33442349-5668596D-FE50-4B9B-A669-ED62DC31A24E Q33593213-26CABC22-C06F-4E41-BAB8-8CADC05BC7F5 Q33594931-ACEDBA09-3EE0-44E1-A21F-D090447394B2 Q33759933-752BDDBA-C1D7-4EC6-A780-A7A6427695F4 Q33761531-8EBA2B25-EBE8-4147-A923-8D4E8A726BFB Q33820667-41F8CA44-6C1E-49C1-A0B2-55429ED63BE9 Q33854034-049E3C49-CCA8-448A-B89B-7FCC099A998E Q33920350-310DE220-7501-4A46-A18C-C0C99E58D0DB Q33964077-A109C2C8-BFD0-4012-96C2-15F92F98601D Q33990018-E1595F11-6408-41C7-BD97-DEE4AA44B5D5 Q34108430-B2E36FEE-B3E5-49B8-ABEC-D228347C7EDD Q34217671-0EE5AA24-D6EE-47E5-8E27-65500F816E46 Q34225158-640B09D7-FD85-4C28-8C5F-0AF9EF55B28B Q34241371-56AE6347-07AB-431A-9A5D-5CAE27E8FB3A Q34438331-6058791A-68E6-43F4-B2E6-BD708A7E1DA8 Q34458029-C06D96B1-AD1F-4E2A-B0E6-62A8875DAAED Q34458068-F291249B-4327-4CF7-84C5-91867A64C21A Q34554398-035A0A07-2C7F-47A8-BDA1-FB8392B2AF21 Q34611731-6E0DD1A5-7BCD-4C78-8D02-E28E419C73B4 Q34695917-DED86ACD-3EAF-4012-AD98-D03601B65FC1 Q34770140-15D8646D-C779-4CC6-B0E2-E050600AC916 Q34928923-F09DB5FE-43DC-4506-B9EC-3C98CCCFAA5B

P2860

Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.

http://www.wikidata.org/entity/Q37809940

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Doxorubicin plus sorafenib vs ...... carcinoma: a randomized trial.

@en

Doxorubicin plus sorafenib vs ...... carcinoma: a randomized trial.

@nl

type

label

Doxorubicin plus sorafenib vs ...... carcinoma: a randomized trial.

@en

Doxorubicin plus sorafenib vs ...... carcinoma: a randomized trial.

@nl

prefLabel

Doxorubicin plus sorafenib vs ...... carcinoma: a randomized trial.

@en

Doxorubicin plus sorafenib vs ...... carcinoma: a randomized trial.

@nl

P1433

Q37809940-F2585F51-75CE-4B06-A09C-8A0A543E795C

P1476

Q37809940-6ECCE057-4D46-44EB-9A6F-5C75799D43BB

P2093

Q37809940-4E10B12C-2099-4F26-9F33-C78F350D956D

Q37809940-5D2735E0-8E25-492E-A28C-4C191DD47FDE

Q37809940-6008B1F8-43EE-4C07-9459-79586004C1C1

Q37809940-910179F4-3523-47D1-8F8F-D462547AE2A6

Q37809940-BDE3BB01-8602-4ED6-A5C8-46C9D0B4475F

Q37809940-C1937B3F-2270-405D-9F72-4172AD3B1F69

Q37809940-DAA1293F-2CAA-4B3F-BC0D-E7A3CAC5C8A7

Q37809940-FD9C612F-78F1-471E-A227-E0B36C93EA29

P304

Q37809940-A84B2A44-8365-4D8D-AA1A-E0BBC5A7A679

P31

Q37809940-2D973CED-45BD-4383-B0BB-63399FEDD94B

P356

Q37809940-2B95FC07-3C86-45FB-A85D-E72129EF62D9

P407

Q37809940-D376FE48-C078-433D-95C5-04F264ACF65C

P433

Q37809940-DD2BD518-AB8A-446F-A3A6-C9F17DFBEDBB

P478

Q37809940-7C9CC254-6B3A-495C-9AA4-5F74CD1BC374

P50

Q37809940-5909521E-2663-4E38-AD11-9D914BAFEEC8

P577

Q37809940-92D73CED-22CF-48AA-BF01-CE55C0056F3A

P5875

Q37809940-5829AFF8-E1C8-428F-A76C-A42AAE9F468F

P698

Q37809940-ACCB3F29-4B7B-4EFD-B311-6B637CE246D9

P921

Q37809940-0C5009CB-FFB4-42D9-90DE-80DAA162B9A4

P356

P1433

Journal of the American Medical Association

P1476

Doxorubicin plus sorafenib vs ...... carcinoma: a randomized trial.

@en

P2093

Bolorsukh Gansukh

http://www.w3.org/2001/XMLSchema#string

Ghassan K Abou-Alfa

http://www.w3.org/2001/XMLSchema#string

Irina Davidenko

http://www.w3.org/2001/XMLSchema#string

Jennifer J Knox

http://www.w3.org/2001/XMLSchema#string

Juan Lacava

http://www.w3.org/2001/XMLSchema#string

Marinela Capanu

http://www.w3.org/2001/XMLSchema#string

Philip Johnson

http://www.w3.org/2001/XMLSchema#string

Thomas Leung

http://www.w3.org/2001/XMLSchema#string

P304

2154-2160

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.2010.1672

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

304

http://www.w3.org/2001/XMLSchema#string

P50

Leonard B. Saltz

P577

2010-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47809220

http://www.w3.org/2001/XMLSchema#string

P698

21081728

http://www.w3.org/2001/XMLSchema#string

P921